预约演示
更新于：2025-12-19
Lacidipine
拉西地平
更新于：2025-12-19
概要
基本信息
原研机构 |
非在研机构- |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 意大利 (1991-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C26H33NO6 |
InChIKeyGKQPCPXONLDCMU-CCEZHUSRSA-N |
CAS号103890-78-4 |
关联
70
项与 拉西地平 相关的临床试验NCT07258693
Multimodal Treatment of Knee Osteoarthritis: Comparison of the Combination of Therapeutic Exercise and Noninvasive Neuromodulation (NESA) Versus Therapeutic Exercise and Transcutaneous Electrical Nerve Stimulation (TENS) on Pain, Function, and Mental Health in People Over 60 Years of Age.
CTR20252748
中国健康受试者单次口服拉西地平片（4mg）的开放、随机、单剂量、两制剂、单次给药、两序列、四周期、完全重复交叉空腹和餐后状态下生物等效性试验
NCT07128875
Effectiveness of Therapeutic Exercises in Reducing Pain and Disability in Knee Osteoarthritis Patients in Older Adults
100 项与 拉西地平 相关的临床结果
登录后查看更多信息
100 项与 拉西地平 相关的转化医学
登录后查看更多信息
100 项与 拉西地平 相关的专利（医药）
登录后查看更多信息
6,769
项与 拉西地平 相关的文献（医药）2026-01-01Cardiology in review
Titin: The Missing Link in Cardiac Physiology
Review
作者: ElSaygh, Jude ; Frishman, William H. ; Peterson, Stephen J. ; Parikh, Manish A. ; Zaher, Anas
Titin, an extraordinary protein known for its colossal size and multifaceted roles, is a cornerstone in the structural and functional dynamics of striated muscle tissues, including the heart and skeletal muscles. Its sheer enormity, with a molecular weight exceeding 3000 kDa, is paralleled only by the immense influence it exerts on muscle physiology. This review will delve into the remarkable structural organization of Titin and the genetics of this molecule, including the common mutations resulting in various cardiomyopathies. We will delve deeper into its role in dilated cardiomyopathy, familial restrictive cardiomyopathy, hypertrophic cardiomyopathy, and left ventricular noncompaction cardiomyopathy. This review culminates by discussing the prospects of therapeutic strategies targeting Titin. While these interventions remain primarily theoretical, the possibilities are intriguing. Patients with Titin truncation mutations present unique challenges, but innovative approaches like gene therapy or preemptive treatments with drugs such as angiotensin-converting enzyme inhibitors or beta-blockers offer hope. This multi-pronged approach highlights the significance of understanding Titin’s multifaceted role and its potential as a target for future therapeutic interventions.
2025-12-31ANNALS OF MEDICINE
Withholding vs. continuing angiotensin-converting enzyme inhibitors or angiotensin receptor blockers before surgery: a systematic review and meta-analysis of randomized controlled trials
Review
作者: Sudhan, Nazneen ; Liu, Hong ; Long, Yu-qin ; Ji, Fu-hai ; Hu, Jing-hui ; Dou, Wei ; Peng, Ke
BACKGROUND:
The optimal preoperative management of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) remains debated. This meta-analysis of randomized controlled trials (RCTs) assessed withholding vs. continuing ACEIs/ARBs on intraoperative hypotension and postoperative outcomes.
METHODS:
PubMed, Web of Science, and China Biology Medicine were comprehensively searched to identify RCTs comparing preoperative withholding ACEIs/ARBs with a continuing therapy in adult patients. Two authors independently extracted and pooled data using a random-effects model. The primary outcome was the incidence of intraoperative hypotension. Secondary outcomes included duration of intraoperative hypotension, vasopressor use, postoperative hypotension and hypertension, major adverse cardiovascular events, acute kidney injury, duration of mechanical ventilation, length of stay in ICU and hospital, and 30-d mortality. Evidence was assessed using the Grading of Recommendations, Assessment, Development and Evaluation approach.
RESULTS:
Fourteen RCTs with 4063 patients were included. Withholding ACEIs/ARBs before noncardiac surgery was associated with a reduced incidence of intraoperative hypotension (36.4% vs. 48.4%; risk ratio = 0.73, 95% confidence interval = 0.60-0.88, p = 0.001, I2 = 63%; a very low certainty of evidence); it was associated with a shorter duration of intraoperative hypotension (mean difference = -5.41 min), reduced vasopressor use (37.5% vs. 51.2%), and increased postoperative hypertension (27.8% vs. 20.2%), without affecting other outcomes (low or very low certainty of evidence).
CONCLUSIONS:
While withholding ACEIs/ARBs may reduce intraoperative hypotension, the very low certainty of evidence underscores the need for future research to confirm clinical implications.
SYSTEMATIC REVIEW REGISTRATION:
PROSPERO (CRD42021253965).
2025-12-31BLOOD PRESSURE
Association between ACEI/ARB and short-term prognosis in dialysis patients with hypertension admitted to intensive care unit
Article
作者: Zheng, Jingang ; Li, Jiahui ; Ye, Zixiang ; Duo, Xiaoyan ; Che, Wuqiang ; Gao, Yanxiang ; An, Shuoyan ; Li, Xingliang
INTRODUCTION:
To investigate the association between angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEI/ARB) and short-term prognosis in dialysis patients with hypertension admitted to intensive care unit (ICU).
METHODS:
Patients with a diagnosis of hypertension and dialysis who received antihypertensive agents during hospitalisation were included. Based on whether treated with ACEI/ARB, patients were divided to ACEI/ARB group and non- ACEI/ARB group. In-hospital mortality and 30-day all-cause mortality were compared between the two groups in the overall participants and after propensity score matching.
RESULTS:
The study included 647 patients, among which 227 (34.70%) were treated with ACEI/ARB. Compared to the non-ACEI/ARB group, fewer patients in the ACEI/ARB group suffered from atrial fibrillation/flutter (17.2% vs 31.9%, p < 0.001). The overall hospital mortality rate was 5.1%, and 9.0% of patients died during the 30-day follow-up period. ACEI/ARB group were with better clinical outcomes during hospitalisation (2.2% vs 6.7%, p = 0.023) and after 30-day follow-up (5.3% vs 11.0%, p = 0.016). ACEI/ARB treatment was independently associated with lower risk of hospital mortality (OR 0.24, 96% CI: 0.051 - 0.82, p = 0.038) and 30-day mortality (HR 0.36, 95% CI:0.15-0.89, p = 0.029) after adjusting confounding factors. After propensity score matching (PSM, 112 pairs), the ACEI/ARB group showed higher in-hospital (99.1% vs 91.1%, p = 0.013) and 30-day (95.5% vs 88.4%, p = 0.048) survival rates compared to the control group. ACEI/ARB was identified as an independent protector for 30-day mortality in the matched cohort (HR 0.33, 95% CI: 0.11-0.95, p = 0.041).
CONCLUSION:
ACEI/ARB treatment showed a significant association with improved in-hospital and 30-day outcomes in dialysis patients with hypertension in the ICU.
100 项与 拉西地平 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 高血压 | 意大利 | 1991-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 原发性高血压 | 临床3期 | - | 1995-06-01 | |
| 稳定型心绞痛 | 临床2期 | - | 1998-04-01 | |
| 溃疡性结肠炎 | 临床前 | 中国 | 2024-09-11 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 315 | 製鹹網夢憲鏇網醖壓壓(鬱鹹艱鏇繭積築廠膚壓) = 願遞鏇襯憲繭構齋廠憲 齋獵網蓋網餘餘鹽願窪 (網鏇蓋衊鹹網齋選醖鹹 ) | - | 2013-06-01 | |||
製鹹網夢憲鏇網醖壓壓(鬱鹹艱鏇繭積築廠膚壓) = 顧鹽衊鏇遞壓鹽齋淵築 齋獵網蓋網餘餘鹽願窪 (網鏇蓋衊鹹網齋選醖鹹 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用